Dibenol
- Brand:Square Pharmaceuticals Ltd.
- Product Code: Dibenol 5 mg
- Availability: In Stock
-
1.00Tk.
Indications
Glibenclamide is used
in the treatment of non insulin dependent diabetes melitus (NIDDM). It is
ineffective in completely pancreatectomized patients and in juvenile-onset type
of diabetes, in which the pancreas has lost all or nearly all of its capacity
to secrete insulin. Such patients require insulin and attempts to control them
with oral therapy are dangerous and doomed to failure.
Pharmacology
Glibenclamide is an
orally effective hypoglycaemic agent that reduces blood sugar concentration by
stimulating secretion of endogenous insulin from the pancreatic β-cells. It
stimulates the mobilization of endogenous insulin with a lower dosage and with
few incidence of side effects that any available anti-diabetic. Hypoglycaemic
action associated with short-term therapy appears to include reduction of basal
hepatic glucose production and enhancement of peripheral insulin action at
target sites.
Dosage & Administration
Initially
stabilization dosage: Glibenclamide half
tablet (2.5 mg) should be taken initially during or immediately after
breakfast. 3-5 days after initiation of the drug, the blood sugar level and
urine sugar level should be checked. Daily dose of ½ tablet (2.5 mg) may be
continued as maintenance therapy if good control has been achieved. If the
result is not good, increment of daily dose in steps of ½ tablet (2.5 mg) is
necessary at intervals of 3-5 days up to a maximum of 3 tablets. Daily doses in
excess of 10 mg may be taken in 2 divided doses. Patients should be given ½ to
1 tablet of Glibenclamide in changing over from other oral anti-diabetics with
a similar action.
Change over from
insulin to Glibenclamide: The mildly diabetic patient whose insulin requirement is fewer
than 20 units daily, can be started on the initial dosage of Glibenclamide with
immediate discontinuation of insulin. If the insulin requirement is moderate or
high, the changeover should be made gradually by giving insulin and
Glibenclamide simultaneously and slowly cutting down the dose of insulin.
When insulin requirements are increased as in fever, surgical interventions or
trauma, the Glibenclamide alone is inadequate and the patient must be given
insulin to carry him or her through such critical situation.
This changeover from insulin to Glibenclamide is strictly for NIDDM of fairly
recent onset which is being controlled on small doses of insulin. This should
preferably be done in hospital or with daily medical supervision.
* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Interaction
Alcohol,
cyclophosphamide, dicoumarol, monoamino oxidase inhibitors, phenylbutazone,
propranolol and other beta-adrenergic blocking agents and certain long-acting
sulphonamides may enhance the hypoglycemic effect of Glibenclamide
Contraindications
Severe metabolic
de-compensation with acidosis, pre-comatose states and diabetic coma, severe
renal or hepatic dysfunction or serious impairment of typhoid or adrenal
function; pregnancy, diabetes mellitus complicated by fever, trauma or
gangrene.
Side Effects
Glibenclamide is well
tolerated. Few side effects that may arise include nausea, vomiting, epigastric
pain, dizziness, weakness, paraesthesia and headache. Allergic skin reactions
and haemopoietic reactions (leukopenia, thrombocytopenia, etc.) are occasionally
observed.
Pregnancy & Lactation
There is no
information on the use of Glibenclamide in human pregnancy but it has been in
wide, general use for many years without apparent ill consequence. Animal
studies have shown no hazard. It has not yet been established whether
Glibenclamide is transferred to human milk. However, other sulphonylureas have
been found in milk and there is no evidence to suggest that Glibenclamide
differs from the group in this respect.
Precautions & Warnings
Weight reduction is of
the greatest importance in the treatment of diabetes. A vigorous effort must be
made by the patient and the physician to reduce the patient's weight as an
integral part of diabetic treatment, irrespective of the drug chosen.
Overdose Effects
Symptoms: Hypoglycaemia.
Management: Mild hypoglycaemic symptoms without loss
of consciousness or neurologic findings may be treated with oral glucose and
adjust drug dosage and/or meal patterns.
Therapeutic Class
Sulfonylureas
Storage Conditions
Should be stored in a
dry place below 30˚ C.
Tags: Dibenol